Recordati SpA operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Recordati SpA with three other
pharmaceutical manufacturers in Europe:
sales of 1.07 billion Euro [US$1.21 billion]
of which 95%
was Pharmaceuticals Business),
Krka DD Novo Mesto
(1.17 billion Euro [US$1.32 billion]
of which 63%
was European Union), and
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Reszvenytarsasag
based in Hungary
(389.69 billion Hungarian Forints [US$1.42 billion]
of which 81%
was Pharmaceutical Manufacturing and Sale).
During the year ended December of 2016, sales at
Recordati SpA were 1.15 billion Euro (US$1.30 billion).
increase of 10.1%
versus 2015, when the company's sales were 1.05 billion Euro.
This was the fifth consecutive year of sales increases at Recordati SpA
(and since 2011, sales have increased a total of 57%).
Sales of Orphan Drugs saw an increase
that was more than double the company's growth rate: sales were up
22.0% in 2016, from
153.13 million Euro to 186.81 million Euro.